Trials / Completed
CompletedNCT02149303
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 191 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
Detailed description
Purpose:
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabigatran 75 mg | PO BID |
| DRUG | Dabigatran 150 mg | PO BID |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2014-05-29
- Last updated
- 2016-04-04
- Results posted
- 2016-04-04
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02149303. Inclusion in this directory is not an endorsement.